Clinical trials: Skin to Skin
Atopic Dermatitis (AD), Psoriasis (PsO)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.
- Trial name
- NCT06982352
- Testing
- LPX-TI641
- Where
- 3 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.
Tinea Pedis
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
- Trial name
- NCT04152226
- Testing
- Janthinobacterium lividum
- Where
- Dominican Republic
- Volunteers
- 12 people
- Sponsor
- DermBiont, Inc.
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Skin Laxity
Rollover Study to Evaluate Histological Results of Radiofrequency Device Treatments on the Flanks
The purpose of this study is to evaluate histological results of the treatments with the TempSure Firm handpiece on the flanks performed in the CYN20-FIRM-LIPO study.
- Trial name
- NCT04881149
- Testing
- TempSure treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cynosure, Inc.
Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in…
- Conditions
- Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- Trial name
- NCT07729826
- Testing
- C-CAR168
- Volunteers
- 50 people
- Sponsor
- AbelZeta Inc.
Rheumatoid Arthritis
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
- Trial name
- AVERT-2 (NCT02504268)
- Testing
- Abatacept, Methotrexate
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 994 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
- Trial name
- UNCOVER-J (NCT01624233)
- Testing
- 80 mg ixekizumab
- Where
- 17 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell…
- Trial name
- NCT00718315
- Testing
- erlotinib [Tarceva], fusidic acid [Verutex], erythromycin [Eritex]
- Where
- 26 sites in Brazil
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Psoriatic Arthritis
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active PsA.
- Trial name
- NCT03320876
- Testing
- filgotinib
- Where
- 25 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 122 people
- Sponsor
- Lakefront Biotherapeutics NV
Palmoplantaris Pustulosis
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
The purpose of this study is to assess the efficacy, safety, and tolerability of CNTO 1959 following subcutaneous administration in participants with palmoplantar pustulosis.
- Trial name
- NCT01845987
- Testing
- CNTO 1959
- Where
- 8 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Rheumatoid Arthritis
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid…
- Trial name
- NCT00747214
- Testing
- CRx-102, DMARD Therapy
- Volunteers
- 59 people
- Sponsor
- Zalicus
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
This single arm study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who are receiving methotrexate treatment, and who have had an inadequate response to one anti-TNF alpha therapy.
- Trial name
- NCT00576433
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 18 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Erythema, Skin Recovery
A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Face Skin to Recover After Cosmetic Lasering
In this study, researchers want to learn more about the effect of dexpanthenol dermal spray on skin recovery and reduction of skin redness after a dermatological procedure (non-ablative laser) on the face for treatment of fine…
- Trial name
- NCT03853538
- Testing
- BAY207543 (Bepanthol, Bepantol® Derma Spray), Semisolid vaseline
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Osteoarthritis (OA) of the Knee, Osteoarthritis Knee Pain
First in Human Study of SakuraBead for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteoarthritis
A prospective, single-centre, single-arm, unmasked, First in Human study that aims to evaluate the safety and efficacy of SakuraBead resorbable microspheres in adult patients suffering from pain secondary to knee osteoarthritis.
- Conditions
- Osteoarthritis (OA) of the Knee, Osteoarthritis Knee Pain, Joint Diseases, Musculoskeletal Diseases
- Trial name
- NCT06718478
- Testing
- SakuraBead Resorbable Microspheres
- Where
- Uzbekistan
- Volunteers
- 15 people
- Sponsor
- CrannMed
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Recurrent Herpes Labialis
A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Researchers are looking for a better way to treat people who have recurrent herpes labialis, also known as cold sores. This is a type of viral infection that causes redness and blisters on the mouth and lip and that recurs.
- Trial name
- NCT05098938
- Testing
- Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
- Where
- United States
- Volunteers
- 2,020 people
- Sponsor
- Bayer
Donor Site Complication
TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Primary objective: 1. To evaluate the safety of TWB-103 in split-thickness skin graft donor site wounds (DSW) for Phase I in terms of Incidence of treatment-related AEs and SAEs (including infections and bleeding) 2.
- Trial name
- NCT02737748
- Testing
- TWB-103 Group
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 48 people
- Sponsor
- Transwell Biotech Co., Ltd.
Dermatitis, Atopic
Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis
The objective of this study is to assess the safety and efficacy of 0.03% tacrolimus ointment as long-term treatment in paediatric patients with atopic dermatitis.
- Trial name
- NCT00560326
- Testing
- Tacrolimus Ointment 0.03%
- Where
- 8 sites in Canada, Finland and 3 more
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.